October 8, 2011AJP Heart and Circulatory Physiology

Erythropoietin protects against doxorubicin-induced heart failure

Q: What is the clinical evidence from this study?

Population: Doxorubicin-induced heart failure. Intervention: Erythropoietin (EPO) vs. Adriamycin (doxorubicin) alone and saline vehicle. Primary outcome: Recovery of cardiac function after ischemia-reperfusion.

View Full Paper

Ask AI

Bookmark

Key result

Erythropoietin treatment effectively prevented doxorubicin-induced heart failure in rats, associated with decreased oxidative stress and apoptosis, and improved myocardial angiogenesis.

Why the study?

Does erythropoietin prevent doxorubicin-induced heart failure in a rat model?

Structured PICO

Does erythropoietin prevent doxorubicin-induced heart failure in a rat model?

Population

Male Wistar rats treated with doxorubicin to induce heart failure, evaluated for the cardioprotective effects of erythropoietin over 4 weeks.

Intervention

Erythropoietin (EPO) subcutaneously at 1,000 IU/kg body wt, three times per week for 4 wk, combined with adriamycin (intraperitoneally at 2.5 mg/kg body wt, three times per week for 2 wk)

Comparator

Adriamycin alone (intraperitoneally at 2.5 mg/kg body wt, three times per week for 2 wk) and saline vehicle control

Outcome

Cardiac function via echocardiography and recovery after ischemia-reperfusion (left ventricular developed pressure, maximal increase in pressure, and rate pressure product)surrogate

Erythropoietin protects against doxorubicin-induced heart failure in rats by reducing oxidative stress and apoptosis while improving myocardial angiogenesis.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Erythropoietin should not yet alter doxorubicin cardiotoxicity management; hypothesis-generating for cardioprotection in animal models.

Cite This Study

Ammar et al. (2011) studied Doxorubicin-induced heart failure. Erythropoietin (EPO) vs. Adriamycin (doxorubicin) alone and saline vehicle was evaluated on Recovery of cardiac function after ischemia-reperfusion. Erythropoietin treatment effectively prevented doxorubicin-induced heart failure in rats, associated with decreased oxidative stress and apoptosis, and improved myocardial angiogenesis.

synapsesocial.com/papers/6a33030f7282da61628075ab https://doi.org/10.1152/ajpheart.01096.2010

Topics

Heart failure HFrEF treatment Bremelanotide

View Full Paper

Ask AI

Bookmark

Erythropoietin protects against doxorubicin-induced heart failure

Structured PICO

Discussion

Implication

Cite This Study

Topics

Erythropoietin protects against doxorubicin-induced heart failure

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Topics

Also Consider